Literature DB >> 15667579

Prognostic impact of low-shear whole blood viscosity in hypertensive men.

G Ciuffetti1, G Schillaci, R Lombardini, M Pirro, G Vaudo, E Mannarino.   

Abstract

BACKGROUND: The role of blood viscosity as a marker for discriminating cardiovascular risk in essential hypertension remains uncertain. The aim of this study was to assess whether whole blood viscosity (WBV) could be useful in assessing cardiovascular risk in men with a first diagnosis of hypertension.
DESIGN: A total of 331 middle-aged men with newly diagnosed essential hypertension (age at entry 40-64 years, average blood pressure 151/95 mmHg) underwent low-shear-rate (0.94 s(-1)) and high-shear-rate (94.5 s(-1)) WBV determination and were then followed for a mean of 4.8 +/- 3 years (range 0-12 years).
RESULTS: Cardiovascular event rates in the bottom, middle and top tertiles of the distribution of low-shear WBV were 1.10, 2.13 and 4.43 per 100 patient-years, respectively (log-rank test, P < 0.001). After taking into account several established cardiovascular risk factors in a Cox survival analysis, a raised low-shear WBV conferred an increased risk for cardiovascular events (top vs. bottom tertile hazard ratio = 3.42, 95% confidence interval = 1.4-8.4, P = 0.006; middle vs. bottom tertile hazard ratio = 2.25, 95% confidence interval = 0.9-5.6, P = 0.09). The independent association between high-shear-rate WBV and cardiovascular events bordered statistical significance (P = 0.07). Inclusion in the survival model of low-shear-rate resulted in a significantly greater chi(2) improvement (P < 0.05) than inclusion of high-shear-rate WBV.
CONCLUSIONS: In hypertensive men, an increased WBV at low shear rate is a predictor of cardiovascular events independently from the effect of several traditional risk factors. Low-shear WBV is a better discriminator of cardiovascular risk than high-shear WBV.

Entities:  

Mesh:

Year:  2005        PMID: 15667579     DOI: 10.1111/j.1365-2362.2005.01437.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

1.  Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?

Authors:  Bihter Senturk; Bahri Akdeniz; Mehmet Birhan Yilmaz; Buse Ozcan Kahraman; Burak Acar; Sadettin Uslu; Merih Birlik
Journal:  Clin Rheumatol       Date:  2019-05-26       Impact factor: 2.980

2.  Association of hyperviscosity and subclinical atherosclerosis in obese schoolchildren.

Authors:  Weihua Zhu; Mengxia Li; Xianmei Huang; Henning Neubauer
Journal:  Eur J Pediatr       Date:  2005-07-12       Impact factor: 3.183

3.  Improvement and Application of Acute Blood Stasis Rat Model Aligned with the 3Rs (Reduction, Refinement and Replacement) of Humane Animal Experimentation.

Authors:  Shuai Huang; Feng Xu; Yin-Ye Wang; Ming-Ying Shang; Chao-Qun Wang; Xuan Wang; Shao-Qing Cai
Journal:  Chin J Integr Med       Date:  2014-12-23       Impact factor: 1.978

Review 4.  Obstructive sleep apnea syndrome: blood viscosity, blood coagulation abnormalities, and early atherosclerosis.

Authors:  Domenico Maurizio Toraldo; Francesco Peverini; Michele De Benedetto; Francesco De Nuccio
Journal:  Lung       Date:  2012-10-18       Impact factor: 2.584

5.  The genetic architecture of adaptations to high altitude in Ethiopia.

Authors:  Gorka Alkorta-Aranburu; Cynthia M Beall; David B Witonsky; Amha Gebremedhin; Jonathan K Pritchard; Anna Di Rienzo
Journal:  PLoS Genet       Date:  2012-12-06       Impact factor: 5.917

6.  Vinpocetine and pyritinol: a new model for blood rheological modulation in cerebrovascular disorders—a randomized controlled clinical study.

Authors:  Hayder M Alkuraishy; Ali I Al-Gareeb; Ali K Albuhadilly
Journal:  Biomed Res Int       Date:  2014-12-07       Impact factor: 3.411

7.  The Epimmunity Theory: The Single Cell Defenses against Infectious and Genetic Diseases.

Authors:  Sameer A Barghouthi
Journal:  Front Immunol       Date:  2017-06-13       Impact factor: 7.561

8.  Blood Viscosity in Subjects With Type 2 Diabetes Mellitus: Roles of Hyperglycemia and Elevated Plasma Fibrinogen.

Authors:  Jiehui Sun; Keqin Han; Miao Xu; Lujuan Li; Jin Qian; Li Li; Xuejin Li
Journal:  Front Physiol       Date:  2022-02-25       Impact factor: 4.566

9.  The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.

Authors:  Chiara Baldini; Francesca Romana Moriconi; Sara Galimberti; Peter Libby; Raffaele De Caterina
Journal:  Eur Heart J       Date:  2021-11-07       Impact factor: 35.855

10.  Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.

Authors:  Kaiyao Shi; Wanke Zhao; Yun Chen; Wanting Tina Ho; Ping Yang; Zhizhuang Joe Zhao
Journal:  J Hematol Oncol       Date:  2014-03-19       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.